Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 18/20 | 0.64 |
| ▸ | DRD3 | P35462 | 12/20 | 0.64 |
| ▸ | HTR2A | P28223 | 4/20 | 0.54 |
| ▸ | HTR1A | P08908 | 3/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491174 | 0.93 | DRD2 (0.65) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL6005640 | 0.91 | HTR1A (0.62) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL11634761 | 0.82 | TMEM97 (0.55) | DRD3HTR2AHTR1A | |
| SCHEMBL3162949 | 0.82 | DRD2 (0.69) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL2201219 | 0.81 | ADAMTS5 (0.55) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL11160437 | 0.80 | ALDH1A1 (0.60) | — | |
| SCHEMBL10763277 | 0.79 | HTR1A (0.65) | HTR2AHTR1A | |
| SCHEMBL3068873 | 0.79 | HTR1A (0.68) | DRD2DRD3HTR1ADRD4 | |
| SCHEMBL11630844 | 0.79 | HTR1A (0.67) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL10365769 | 0.79 | DRD2 (0.61) | DRD2DRD3HTR2AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247420-B2 | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| EP-2162135-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS | Reviva Pharmaceuticals, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008144764-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | GRIN2D, GRIN2C, AP3D1 | DRD2 26/4885DRD3 64/4885HTR2A 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.